Similar articles

• Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

  Vizirianakis IS, Chatzopoulou M, Bonovolias ID, Nicolaou I, Demopoulos VJ, Tsiftsoglou AS. Vizirianakis IS, et al. J Med Chem. 2010 Oct 14;53(19):6779-810. doi: 10.1021/jm100189a. J Med Chem. 2010. PMID: 20925433 Review. No abstract available.
• Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.

  Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, McCubrey JA. Martelli AM, et al. Leukemia. 2011 Jul;25(7):1064-79. doi: 10.1038/leu.2011.46. Epub 2011 Mar 25. Leukemia. 2011. PMID: 21436840 Review.
• miR-138 might reverse multidrug resistance of leukemia cells.

  Zhao X, Yang L, Hu J, Ruan J. Zhao X, et al. Leuk Res. 2010 Aug;34(8):1078-82. doi: 10.1016/j.leukres.2009.10.002. Epub 2009 Nov 6. Leuk Res. 2010. PMID: 19896708
• Resistance to apoptosis induced by serum depletion and all-trans retinoic acid in drug-resistant leukemic cell lines.

  Kakihara T, Fukuda T, Kamishima T, Naito M, Tanaka A, Uchiyama M, Kishi K. Kakihara T, et al. Leuk Lymphoma. 1997 Jul;26(3-4):369-76. doi: 10.3109/10428199709051787. Leuk Lymphoma. 1997. PMID: 9322900
• Pharmacological activation of wild-type p53 in the therapy of leukemia.

  Kojima K, Ishizawa J, Andreeff M. Kojima K, et al. Exp Hematol. 2016 Sep;44(9):791-798. doi: 10.1016/j.exphem.2016.05.014. Epub 2016 Jun 18. Exp Hematol. 2016. PMID: 27327543 Free PMC article. Review.